NEO NeoGenomics Inc: Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

The foundation of NeoGenomics, Inc. (NEO) is the synergy of leading geneticists and pathologists united by a mission to fight cancer. On the GURU.Markets platform, the enterprise value to EBITDA multiple visualizes the capital valuation trend, where the current mark is 138.34. NeoGenomics, Inc. (NEO) strives for dominance in the complex oncology testing segment through IT platforms, leveraging steady demand growth within the hospital sector.
Rincian analitis lan laporan data perusahaan neogenomics.com (NEO)

NeoGenomics, Inc. (NEO) operates as a specialized B2B oncology diagnostics ecosystem whose margins are constrained by strict PAMA government rate regulations. This ratio compares the total enterprise value, including debt load, to earnings before interest, taxes, depreciation, and amortization, allowing investors to assess the asset's real value. Analyzing the business's EV/EBITDA multiple helps identify entry points at historical lows to maximize returns.